Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease

Vaccine

Volumn 24, Issue SUPPL. 3, 2006, Pages

  Lacey, Charles J N ^a   Lowndes, Catherine M ^b   Shah, Keerti V ^c  

^a UNIVERSITY OF YORK   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

HPV 6 11; Management; Non cancerous

Indexed keywords

3 INDOLEMETHANOL; ALPHA INTERFERON; CELECOXIB; CIDOFOVIR; DNA VACCINE; FLUOROURACIL; IMIQUIMOD; INTERFERON; MUMPS VACCINE; PODOPHYLLIN; PODOPHYLLOTOXIN; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG; WART VIRUS VACCINE; WART VIRUS VACCINE L2E7;

AGE DISTRIBUTION; ARTICLE; BEHAVIOR CHANGE; CLINICAL TRIAL; CONDYLOMA; COST EFFECTIVENESS ANALYSIS; CRYOTHERAPY; CURETTAGE; ELECTROSURGERY; EPIDEMIOLOGICAL DATA; EXCISION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; LARYNX PAPILLOMATOSIS; LOW LEVEL LASER THERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU; VIRUS PARTICLE; VIRUS REPLICATION; CONDYLOMA ACUMINATUM; ISOLATION AND PURIFICATION; PAPILLOMA; RESPIRATORY TRACT DISEASE; REVIEW; VIROLOGY; VIRUS INFECTION;

CONDYLOMATA ACUMINATA; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMA; PAPILLOMAVIRUS INFECTIONS; RESPIRATORY TRACT DISEASES;

EID: 33747892746     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.06.015     Document Type: Article

References (40)

1. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and Zur H.H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
2. Gross G., Ikenberg H., Gissmann L., and Hagedorn M. Papillomavirus infection of the anogenital region: correlation between histology, clinical picture, and virus type. Proposal of a new nomenclature. J Invest Dermatol 85 2 (1985) 147-152
3. Lacey C.J. Therapy for genital human papillomavirus-related disease. J Clin Virol 32 Suppl 1 (2005) S82-S90
4. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., et al. Randomised controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192 12 (2005) 2099-2107
5. Munk C., Svare E.I., Poll P., Bock J.E., and Kjaer S.K. History of genital warts in 10,838 women 20 to 29 years of age from the general population. Risk factors and association with Papanicolaou smear history. Sex Transm Dis 24 10 (1997) 567-572
6. Habel L.A., Van Den Eeden S.K., Sherman K.J., McKnight B., Stergachis A., and Daling J.R. Risk factors for incident and recurrent condylomata acuminata among women. A population-based study. Sex Transm Dis 25 6 (1998) 285-292
7. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29 11 (2002) 725-735
8. Barton S.E., Maddox P.H., Jenkins D., Edwards R., Cuzick J., and Singer A. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change?. Lancet 2 8612 (1988) 652-654
9. Monteiro E.F., Lacey C.J., and Merrick D. The interrelation of demographic and geospatial risk factors between four common sexually transmitted diseases. Sex Transm Infect 81 1 (2005) 41-46
10. Holmberg S.D., Buchbinder S.P., Conley L.J., Wong L.C., Katz M.H., Penley K.A., et al. The spectrum of medical conditions and symptoms before acquired immunodeficiency syndrome in homosexual and bisexual men infected with the human immunodeficiency virus. Am J Epidemiol 141 5 (1995) 395-404
11. Silverberg M.J., Ahdieh L., Munoz A., Anastos K., Burk R.D., Cu-Uvin S., et al. The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis 29 8 (2002) 427-435
12. http://www.hpa.org.uk/infections/topics_az/hiv_and_sti/sti-warts/epidemiology/epidemiology.htm
13. Fenton K.A., Korovessis C., Johnson A.M., McCadden A., McManus S., Wellings K., et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection. Lancet 358 9296 (2001) 1851-1854
14. Wellings K., Nanchahal K., Macdowall W., McManus S., Erens B., Mercer C.H., et al. Sexual behaviour in Britain: early heterosexual experience. Lancet 358 9296 (2001) 1843-1850
15. http://www.cdc.gov/std/stats/tables/table47.htm
16. Mayaud P., Gill D.K., Weiss H.A., Uledi E., Kopwe L., Todd J., et al. The interrelation of HIV, cervical human papillomavirus, and neoplasia among antenatal clinic attenders in Tanzania. Sex Transm Infect 77 4 (2001) 248-254
17. Klaskala W., Brayfield B.P., Kankasa C., Bhat G., West J.T., Mitchell C.D., et al. Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia. J Med Virol 75 1 (2005) 93-100
18. Johnston A., Fernando D., and MacBride-Stewart G. Sexually transmitted infections in New Zealand in 2003. N Z Med J 118 1211 (2005) U1347
19. Lacey C.J., Goodall R.L., Tennvall G.R., Maw R., Kinghorn G.R., Fisk P.G., et al. Randomised controlled trial and economic evaluation of podophyllotoxin solution, podophyllotoxin cream, and podophyllin in the treatment of genital warts. Sex Transm Infect 79 4 (2003) 270-275
20. Edwards L., Ferenczy A., Eron L., Baker D., Owens M.L., Fox T.L., et al. Self-administered topical 5% Imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. Arch Dermatol 134 1 (1998) 25-30
21. Moore R.A., Walcott S., White K.L., Anderson D.M., Jain S., Lloyd A., et al. Therapeutic immunisation with COPV early genes by epithelial DNA delivery. Virology 314 2 (2003) 630-635
22. http://www.cdc.gov/STD/treatment/6-2002TG.htm#HumanPapillomavirusInfection
23. http://www.bashh.org/guidelines/2002/hpv_0302b.pdf
24. von Krogh G., Lacey C.J., Gross G., Barrasso R., and Schneider A. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. Sex Transm Infect 76 3 (2000) 162-168
25. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 5 (2005) 1157-1164
26. Armstrong L.R., Derkay C.S., and Reeves W.C. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg 125 7 (1999) 743-748
27. Derkay C.S. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg 121 12 (1995) 1386-1391
28. Shah K.V., Unger E.R., Derkay C.S., and Steinberg B.M. Recurrent respiratory papillomatosis: bright prospects for vaccine-based prevention. Papillomavirus Rep 16 (2005) 333-338
29. Silverberg M.J., Thorsen P., Lindeberg H., Grant L.A., and Shah K.V. Condyloma in pregnancy is strongly predictive of juvenile-onset recurrent respiratory papillomatosis. Obstet Gynecol 101 4 (2003) 645-652
30. Wiatrak B.J., Wiatrak D.W., Broker T.R., and Lewis L. Recurrent respiratory papillomatosis: a longitudinal study comparing severity associated with human papilloma viral types 6 and 11 and other risk factors in a large pediatric population. Laryngoscope 114 11 Pt 2 Suppl 104 (2004) 1-23
31. Reidy P.M., Dedo H.H., Rabah R., Field J.B., Mathog R.H., Gregoire L., et al. Integration of human papillomavirus type 11 in recurrent respiratory papilloma-associated cancer. Laryngoscope 114 11 (2004) 1906-1909
32. Abramson A.L., Nouri M., Mullooly V., Fisch G., and Steinberg B.M. Latent Human Papillomavirus infection is comparable in the larynx and trachea. J Med Virol 72 3 (2004) 473-477
33. Silverberg M.J., Thorsen P., Lindeberg H., Ahdieh-Grant L., and Shah K.V. Clinical course of recurrent respiratory papillomatosis in Danish children. Arch Otolaryngol Head Neck Surg 130 6 (2004) 711-716
34. Lee J.H., and Smith R.J. Recurrent respiratory papillomatosis: pathogenesis to treatment. Curr Opin Otolaryngol Head Neck Surg 13 6 (2005) 354-359
35. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
36. Sattler C. for the FUTURE I investigators. Efficacy of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle vaccine for prevention of cervical dysplasia and external genital lesions. Proceedings of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (2005)
37. http://www.cdc.gov/nip/ACIP/mtg-slides-feb06.htm#hpv
38. Insinga R.P., Dasbach E.J., and Myers E.R. The health and economic burden of genital warts in a set of private health plans in the United States. Clin Infect Dis 36 11 (2003) 1397-1403
39. Langley P.C., White D.J., and Drake S.M. The costs of treating external genital warts in England and Wales: a treatment pattern analysis. Int J STD AIDS 15 8 (2004) 501-508
40. Insinga R.P., Dasbach E.J., and Elbasha E.H. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 23 11 (2005) 1107-1122